N. Shimohata and S. Nagamori contributed equally to this paper.

N. Shimohata\'s present address is Department of Molecular Cell Biology, Graduate School of Medicine, Osaka City University, Abeno-ku, Osaka 545-8585, Japan.

Abbreviations used in this paper: IMV, inverted membrane vesicle; PSBT, 1.3 S subunit of *Propionibacterium shermanii* biotin transcarboxylase; SRP, signal recognition particle; TM, transmembrane.

Introduction
============

Newly synthesized membrane proteins in *Escherichia coli* are believed to be delivered by the signal recognition particle (SRP) to the SecYEG translocon cotranslationally ([@bib30]; for review see [@bib31]). Thus, the SecYEG translocon is used both for the transport of secretory proteins from the cytosol to the periplasm ([@bib40]) and for the integration of membrane proteins (for reviews see [@bib12]; [@bib50]). However, the role of SecYEG in the latter is only poorly understood. It is assumed that a signal-anchor sequence or a stop-transfer hydrophobic segment of a membrane protein is inserted into the translocon first and then moves laterally and is integrated stably into the lipid bilayer. In the processes of membrane protein integration/assembly, an integral membrane protein, YidC, also plays crucial roles ([@bib13]). Although integration of a class of membrane proteins is mediated directly by YidC, other membrane proteins are believed to be inserted first into the SecYEG channel and are transferred to YidC, which will facilitate final anchoring into the lipid phase ([@bib63]) or folding into physiologic conformations ([@bib45]). The SecDF--YajC complex has large periplasmic domains and interacts with both SecYEG and YidC ([@bib47]; [@bib66]). It is thought to mediate the interplay between SecYEG and YidC.

According to the crystal structure of the SecYEβ translocon from an archaea ([@bib64]), an hourglass-shaped polypeptide-conducting channel is formed within the SecY subunit of the heterotrimer in which two halves of SecY are arranged in a pseudosymmetrical manner. It was proposed that the front side of the complex can be opened laterally for the exit of hydrophobic segments of newly synthesized proteins from the translocon to enter the hydrophobic environment. To maintain the impermeability of the membrane to ions, the conductance of the translocon is proposed to be blocked by a plug that covers the pore from the periplasmic side in the resting state and by a ring of hydrophobic residues in the pore that forms a seal around the translocating peptide chain. Despite this remarkable progress, several questions remain about translocon function in membrane protein integration. (1) What are the pathways from the translocon into either the periplasm or the membrane for exported versus membrane proteins, respectively? (2) What are the mechanisms by which movement of a membrane protein in the vertical direction is redirected to lateral transfer toward the lipid phase? (3) Is the translocon sufficiently flexible to allow the reorientation of hydrophobic helices ([@bib18]; [@bib19])? (4) How and when do lipid interactions occur to generate the final topology ([@bib22])?

Whatever the mechanisms involved, it is likely that membrane protein assembly involves thermodynamic partitioning and is catalyzed by proteinaceous machinery (for review see [@bib50]; [@bib22]). Given the requirement for macromolecules, the system may be sensitive to environmental stresses and substrate overloading. Although cells have a regulatory mechanism to cope with defects in biogenesis, little is known about the system that deals with abnormalities in membrane proteins. *E. coli* possesses two extracytoplasmic stress response pathways called Cpx and σ^E^, which up-regulate the expression of a class of proteins involved in folding and proteolysis ([@bib5]; [@bib6]; [@bib15]; [@bib16]). Both systems were shown to sense abnormal proteins in either the outer membrane or the periplasmic space ([@bib15]). Additionally, we have shown that the Cpx/σ^E^ systems sense the accumulation of certain abnormal plasma membrane proteins. For example, the lack of FtsH, a membrane-bound protease, results in up-regulation of the Cpx stress response pathway, which is exaggerated by the overproduction of a membrane protein substrate of FtsH ([@bib56]).

In this study, we describe a class of *secY* missense mutants that are defective in the correct assembly of membrane proteins. Notably, these *secY* mutations up-regulate the Cpx/σ^E^ pathways, as does the depletion of YidC. In vitro experiments reveal that membrane vesicles containing the mutated forms of SecY do not support correct folding of the lactose permease of *E. coli* (LacY), a polytopic membrane protein of known structure ([@bib1]; [@bib37]). It is suggested that in addition to the known function of accepting newly synthesized membrane proteins, SecY also plays a role in their folding into the native conformation.

Results
=======

Defective assembly of plasma membrane proteins up-regulates the Cpx and σ^E^ stress response pathways
-----------------------------------------------------------------------------------------------------

We showed previously that the accumulation of certain classes of membrane proteins under the conditions of compromised activities of quality control proteases results in up-regulation of the Cpx extracytoplasmic stress response ([@bib56]). We reasoned that the stress response mechanism can sense some abnormal states of plasma membrane proteins. To further explore this notion, we examined whether extracytoplasmic stress response is induced when a cellular factor for membrane protein assembly/folding is functionally impaired. For this purpose, we used the arabinose-controlled expression system of YidC ([@bib53]). When arabinose was removed from the medium, YidC abundance in the engineered strain decreased with time ([Fig. 1 A](#fig1){ref-type="fig"}, lanes 5--8). In parallel to this decrease, Cpx pathway gene expression elevated up to about fourfold ([Fig. 1 B](#fig1){ref-type="fig"}, closed circles). Another assay using a reporter of the σ^E^ pathway showed that YidC-deficient conditions also up-regulate this stress response pathway ([Fig. 1 C](#fig1){ref-type="fig"}, closed circles).

![**The *yidC* defect up-regulates extracytoplasmic stress responses.** Plasmid pSH10 (*cpxP*′-*lacZ* ^+^; A and B) or pSTD643 (*rpoHP3*-*lacZ* ^+^; C) was introduced into JS71 (*yidC* ^+^ P~ara~-*yidC*; A, lanes 1--4; B and C, open circles) and JS7131 (Δ*yidC* P~ara~-*yidC*; A, lanes 5--8; B and C, closed circles). The plasmid-bearing cells were grown first in the presence of 0.2% arabinose, washed twice with arabinose-free medium, and grown further in the absence of arabinose for the indicated periods of time. Samples were processed for SDS-PAGE and anti-YidC immunoblotting (A) as well as for β-galactosidase measurements (B and C). The asterisk in A indicates a band of a nonspecific background protein.](jcb1760307f01){#fig1}

A previous study indicates that YidC depletion results in the defective folding of a multipath membrane protein, LacY ([@bib45]). It is also known that YidC is associated with the SecYEG translocon via the SecDF--YajC complex ([@bib47]; [@bib66]). We found that the *secD1* mutation ([@bib17]), which decreases the expression level of the *secD--secF* operon (Chiba, K., personal communication), also induces the Cpx stress response markedly ([Fig. 2 B](#fig2){ref-type="fig"}, third bar). In parallel, we observed that this mutation considerably impaired the insertion of a model membrane protein, MalF--PSBT(J) (1.3 S subunit of *Propionibacterium shermanii* biotin transcarboxylase (J); [Fig. 2 A](#fig2){ref-type="fig"}, lane 3; see the next section and Materials and methods for the significance of this indication of insertion defect). From these results, we surmise that the YidC and SecD deficiencies result in the generation of some aberrant forms of membrane proteins, which, in turn, activate the extracytoplasmic stress response mechanisms.

![**Stress response induction does not always accompany defects in membrane protein integration.** (A) Effects of different *sec* mutations on MalF-PSBT insertion. Plasmids pSTD343 (*lacI* ^q^) and pGJ78-J (MalF-PSBT(J)) were introduced into SH463 (*sec* ^+^), NH192 (*secE501*), SH625 (*secD1*), and KI200 (*rplO215*). The plasmid-bearing cells were grown at 30°C, induced with IPTG for 1 h, and analyzed for biotinylation (top) and accumulation (bottom) of the fusion protein. (B) Effects on Cpx pathway activation. Plasmid pSH10 (*cpxP*′-*lacZ* ^+^) was introduced into the *sec* ^+^, *secE501*, *secD1*, and *rplO215* strains for β-galactosidase measurements at 30°C. (C) Effects on the SecY contents. Portions of cultures used in B were examined by SDS-PAGE and anti-SecY immunoblotting. The graph shows the cellular contents of SecY relative to the wild-type abundance. (D) The *ffh10*(Ts) mutation does not activate the Cpx pathway. Plasmid pSH10 (*cpxP*′-*lacZ* ^+^) was introduced into SKP1101 (*ffh10*(Ts)) and SKP1102 (*ffh* ^+^). The plasmid-bearing cells were grown first at 30°C and then were shifted to 42°C for 1 h for the measurement of β-galactosidase activities. Error bars represent SD.](jcb1760307f02){#fig2}

The roles of YidC and SecD in membrane protein biogenesis are probably at stages after the initial targeting of newly synthesized membrane proteins. Defects at the targeting steps caused by an SRP mutation is known to induce the σ^32^-dependent cytosolic stress response, presumably by producing uninserted membrane proteins in the cytosolic part of the cell ([@bib9]; [@bib48]). To examine the effects of a defect in the SRP-targeting factor on the envelope stress response, we used the *ffh10*(Ts) mutation ([@bib48]). It was found that these mutant cells contained lower than normal levels of the Cpx-controlled LacZ activity ([Fig. 2 D](#fig2){ref-type="fig"}). Thus, this mutation in the targeting factor does not up-regulate the Cpx extracytoplasmic stress response. We also examined the consequence of a simple reduction of the cellular abundance of the translocon. The *rplO215*(*amber*) mutation ([@bib24]), which decreases the expression level of SecY by ∼70% ([Fig. 2 C](#fig2){ref-type="fig"}, lane 4), did not activate the Cpx pathway at all ([Fig. 2 B](#fig2){ref-type="fig"}, fourth bar), although a model membrane protein, MalF-PSBT(J), exhibited a considerable insertion defect in this mutant ([Fig. 2 A](#fig2){ref-type="fig"}, lane 4). Also, the *secE501* mutation, which decreases *secE* expression ([@bib54]) and consequently leads to rapid degradation of the uncomplexed fraction of SecY ([Fig. 2 C](#fig2){ref-type="fig"}, lane 2; [@bib61]), impaired insertion of the model membrane protein ([Fig. 2 A](#fig2){ref-type="fig"}, lane 2) but activated the stress response only insignificantly ([Fig. 2 B](#fig2){ref-type="fig"}, second column). These results indicate that the lack of insertion process itself does not generate a membrane stress. Collectively, we suggest that membrane protein folding/assembly defects that occur within the plasma membrane after the targeting event lead to the up-regulated envelope stress responses.

Strategy to classify defects in membrane protein biogenesis
-----------------------------------------------------------

Membrane protein biogenesis is accomplished by a series of sequential steps: translation, targeting, translocation via the translocon, lateral exit from the translocon, folding, assembly, and stable integration into the membrane. Although previous genetic and biochemical studies revealed cellular mechanisms that mediate these steps (for reviews see [@bib12]; [@bib31]), these studies primarily addressed whether a particular model membrane protein was inserted into the membrane with the proper topology of the extracytoplasmic domain. In most cases, defects in the pathway were detected only by the accumulation of uninserted molecules. In this study, we use the term type 1 defect to describe this phenomenon (Fig. S1, available at <http://www.jcb.org/cgi/content/full/jcb.200611121/DC1>). A defect in subsequent steps can occlude the translocon or interfere with earlier steps in the pathway (i.e., by backup). As the biogenesis pathway is constantly loaded with newly synthesized proteins, the accumulation of uninserted molecules can result not only when the primary defect is at the targeting step but also when the defect is at a later stage (Fig. S1). In other words, a defect in any step of the pathway can appear to be type 1.

From the results presented in the preceding section, we suggest that the induction of envelope stress responses can be used as a specific indicator of postinsertion defects such as folding and assembly. We use the term type 2 defect for this phenomenon. Although a membrane stress response may suggest a postinsertion defect, a more direct demonstration of the folding/assembly failure is required. To demonstrate this point, we use the system of [@bib44], [@bib45]), in which in vitro translation of LacY is coupled to insertion into the membrane and folding into the tertiary structure, which is recognized by conformation-specific mAbs. We use the term type 3 defect to describe a failure that is detectable by this assay (Fig. S1). It should be noted that the in vitro system would suffer minimally from the backup phenomena because it uses very minute amounts of radiolabeled membrane protein. In the following analyses of *secY* mutations, we used the MalF-PSBT(J) fusion protein (see Materials and methods; [@bib25]) and the SecY-PhoA C6 fusion protein (Fig. S2; [@bib4]) to reveal the type 1 defect, induction of the Cpx/σ^E^ stress response to identify the type 2 defect, and acquisition of conformational epitopes in LacY to identify the type 3 defect.

Mutations in *secY* that impair the integration function do not correlate with those impairing export function
--------------------------------------------------------------------------------------------------------------

We examined a series of *secY* mutants that were described previously ([@bib62]) as well as additional *secY* mutants isolated in this study (see Materials and methods and [Table I](#tbl1){ref-type="table"}) with respect to their defects in protein export and in membrane protein insertion (type 1 defect). These mutants were originally isolated as those up-regulating either a secretion monitor reporter ([@bib62]) or a membrane stress reporter (see Materials and methods) at 37 or 30°C. Whereas many of them are either cold sensitive or temperature sensitive for growth, we assessed their export/integration phenotypes at the growth-allowing temperature (37 or 30°C), at which their lesion had been recognized by the original screening procedures. The export of OmpA, as examined by pulse labeling and immunoprecipitation, was evidently retarded in the *secY39*, *secY205*, *secY125*, and *secY124* mutants ([Fig. 3 A](#fig3){ref-type="fig"}, lanes 2--5) but was much less pronouncedly retarded in the *secY40*, *secY129*, *secY238*, *secY299*, *secY351*, and *secY403* mutants ([Fig. 3 A](#fig3){ref-type="fig"}, lanes 6, 7, and 9--12). The export of maltose-binding protein showed *secY* dependence similar to that of OmpA (unpublished data).

###### 

**SecY alterations characterized in this study**

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Allele name                                                                               Amino acid change                        Domain affected       OmpA export   MalF-PSBT insertion   Cpx/σ^E^ stress   LacY folding   LacY stability
  ----------------------------------------------------------------------------------------- ---------------------------------------- --------------------- ------------- --------------------- ----------------- -------------- ----------------
  *secY* ^+^                                                                                None                                     None                  \+            \+                    --                \+             \+

  *secY125* [a](#tblfn1){ref-type="table-fn"}                                               S76F[a](#tblfn1){ref-type="table-fn"}    P1 (TM2a)             --            --                    \+                --             --

  *secY124*, *secY84* [a](#tblfn1){ref-type="table-fn"} [b](#tblfn2){ref-type="table-fn"}   P84L[a](#tblfn1){ref-type="table-fn"}    TM2                   --            --                    \+                NT             NT

  *secY238* [a](#tblfn1){ref-type="table-fn"} [b](#tblfn2){ref-type="table-fn"}             E238K[a](#tblfn1){ref-type="table-fn"}   TM6/C4                (+)           --                    \+                --             --

  *secY299* [b](#tblfn2){ref-type="table-fn"}                                               G299D                                    P4                    (+)           --                    (−)               NT             NT

  *secY351* [a](#tblfn1){ref-type="table-fn"} [b](#tblfn2){ref-type="table-fn"}             A351T[a](#tblfn1){ref-type="table-fn"}   C5                    (+)           --                    \+                NT             NT

  *secY39*                                                                                  R357H                                    C5                    --            \+                    --                \+             \+

  *secY40*                                                                                  A363T                                    C5                    (+)           --                    (−)               \+             \+

  *secY129* [a](#tblfn1){ref-type="table-fn"}                                               C385Y[a](#tblfn1){ref-type="table-fn"}   TM9                   (+)           --                    \+                --             --

  *secY403* [b](#tblfn2){ref-type="table-fn"}                                               G403R                                    TM10                  (+)           --                    (−)               NT             NT

  *secY205*                                                                                 Y429D                                    C6                    --            \+                    --                \+             \+

  *rplO215*                                                                                 None\                                    None\                 --            --                    --                NT             NT
                                                                                                (low abundance)                          (low abundance)                                                                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In the third column, SecY domains are indicated by TM, C, and P for transmembrane, cytoplasmic, and periplasmic domains, respectively, numbered from the N terminus in this order. In the fourth and fifth columns, -- indicates a considerable defect, + indicates no defect, and (+) indicates a weak defect. In the sixth column, + indicates considerable induction, -- indicates no induction, and (−) indicates weak induction. In the seventh column, + and − indicate normal and defective folding, respectively. In the last column, + and − indicate normal and decreased stability, respectively. NT, not tested.

Stress response inducers, which are referred to as membrane protein folding--defective mutants in this paper.

Mutations newly identified in this study by the stress response--based screening described in Materials and methods. The *rplO21*5*(amber)* mutation reduces the expression level of SecY.

![**Effects of *secY* mutations on the export of OmpA and insertion of MalF-PSBT(J).** (A) Pulse-labeling analyses of OmpA export. Cells of SH463 (*secY* ^+^), SH470 (*secY39*), SH464 (*secY205*), SH465 (*secY125*), SH466 (*secY124*), SH467 (*secY40*), SH468 (*secY129*), SH117 (*secY* ^+^), SH237 (*secY238*), SH245 (*secY299*), SH247 (*secY351*), and SH253 (*secY403*) were pulse labeled at 37°C with \[^35^S\]methionine for 30 s. OmpA was immunoprecipitated and separated by SDS-PAGE into precursor (p) and mature (m) forms. Numbers below each lane show the proportions of radioactivity associated with the mature form after correction for the methionine contents. (B) Biotinylation analyses of MalF-PSBT(J) insertion. Plasmids pSTD343 (*lacI* ^q^) and pGJ78-J (MalF-PSBT(J) fusion protein) were introduced into SH463 (*secY* ^+^), SH470 (*secY39*), SH464 (*secY205*), SH465 (*secY125*), SH466 (*secY124*), SH467 (*secY40*), SH468 (*secY129*), SH469 (*secY238*), SH471 (*secY299*), SH472 (*secY351*), and SH253 (*secY403*). The plasmid-bearing cells were grown at 37°C and induced with IPTG for 1 h. After separation by SDS-PAGE, the MalF fusion proteins were visualized with anti-MalF (bottom), and their biotinylated fractions (Bt-MalF-PSBT(J)) were visualized with streptavidin-conjugated HRP (top). (C) OmpA export in MalF-PSBT(J)--induced cells. The indicated *secY* mutants, each carrying pSTD343 (*lacI* ^q^) and pGJ78-J (MalF-PSBT(J)), were grown at 37°C either with (bottom) or without (top) IPTG induction for 1 h. Cells were pulse labeled for 30 s and processed for anti-OmpA immunoprecipitation. Similar results for experiments A--C were obtained at 30°C.](jcb1760307f03){#fig3}

We assessed membrane protein insertion phenotypes of the mutants using MalF-PSBT(J) and SecY-PhoA(3-3). These two model membrane proteins gave consistent results, and results with the latter are presented in Fig. S2 (A and B; available at <http://www.jcb.org/cgi/content/full/jcb.200611121/DC1>). All of the mutant strains were normal in biotinylating a control fusion protein (MalF-PSBT(K)) that had the PSBT domain on the cytosolic side (unpublished data). In contrast, MalF-PSBT(J), having PSBT on the periplasmic side, was not appreciably biotinylated in the *secY* ^+^, *secY39*, or *secY205* cells ([Fig. 3 B](#fig3){ref-type="fig"}, top; first to third lanes), in which the fusion protein itself, as visualized by anti-MalF immunoblotting, accumulated normally ([Fig. 3 B](#fig3){ref-type="fig"}, bottom). Remarkably, the integration process appeared to have proceeded normally in the two strongly export-defective mutants, *secY39* and *secY205*. The remaining *secY* mutants examined all proved to be considerably defective in the integration process, as indicated by appreciable biotinylation of the fusion protein ([Fig. 3 B](#fig3){ref-type="fig"}, fourth to seventh lanes and ninth to twelfth lanes).

The aforementioned results allow classification of the *secY* mutations into three groups. First, the *secY39* and *secY205* mutations are severely defective in export but are nearly normal in integration (see Fig. S2 B for the normal kinetics of SecY-PhoA processing in *secY39*). Second, *secY40*, *secY129*, *secY238*, *secY299*, *secY351*, and *secY403* are nearly normal in export but are considerably defective in integration. Finally, *secY125* and *secY124* are defective in both processes. We also examined OmpA export in the presence of simultaneously expressed MalF-PSBT. In this case, export was considerably retarded even in the *secY40* and *secY129* mutants ([Fig. 3 C](#fig3){ref-type="fig"}, bottom; lanes 6 and 7) but not in the wild-type cells ([Fig. 3 C](#fig3){ref-type="fig"}, lane 1). Overproduced MalF-PSBT seems to occlude even the relatively normal export pathway of the translocons having these alterations. As already discussed in the previous section, the accumulation of untranslocated MalF-PSBT observed in some of the *secY* mutants studied in [Fig. 3 B](#fig3){ref-type="fig"} may have been produced secondarily by the primary defect that lies in a later step of the biogenesis pathway.

Membrane stresses are generated in some *secY* mutants
------------------------------------------------------

We then proceeded to screen the *secY* mutants by monitoring the type 2 defect. Thus, we combined each of the aforementioned *secY* mutations with a LacZ reporter, *cpxP\'-lacZ*, of the Cpx stress response pathway ([@bib14]). LacZ (β-galactosidase) levels were found to be elevated appreciably in the *secY125*, *secY124*, *secY129*, *secY238*, and *secY351* mutants ([Fig. 4](#fig4){ref-type="fig"}). The extent of this induction was approximately threefold for *secY125* and *secY238*, which was comparable with the extent of induction observed with the *cpxA24* constitutive mutant ([@bib56]). In contrast, the Cpx pathway was not strongly up-regulated in the *secY40*, *secY299*, or *secY403* mutant (not depicted for *secY403*) despite their integration defects. Stress response was not at all induced in the export^−^ integration^+^ mutant *secY39* or *secY205* ([Fig. 4 C](#fig4){ref-type="fig"}). The σ^E^ pathway was also up-regulated in *secY125* but not in *secY205* (unpublished data). Thus, a class of integration-impairing *secY* mutations activates the stress response mechanisms ([Table I](#tbl1){ref-type="table"}).

![**Effects of *secY* mutations on the Cpx stress response.** Plasmid pSH10 (*cpxP\'*-*lacZ* ^+^) was introduced into SH463 (*secY* ^+^), SH470 (*secY39*), SH464 (*secY205*), SH465 (*secY125*), SH466 (*secY124*), SH467 (*secY40*), SH468 (*secY129*), SH469 (*secY238*), SH472 (*secY299*), and SH471 (*secY351*). Cells were then grown at 30°C, and their β-galactosidase activities were assayed. Similar results were obtained at 37°C. Error bars represent SD.](jcb1760307f04){#fig4}

The LacY folding assay establishes membrane protein folding--impairing *secY* mutations
---------------------------------------------------------------------------------------

To study the type 3 defect, we used LacY, a polytopic membrane protein of known 3D structure ([@bib1]). Inverted membrane vesicles (IMVs) were prepared from cells in which the stress response induction was not markedly observed (*secY* ^+^, *secY39*, *secY205*, and *secY40*) as well as from cells in which the stress response induction was evidently observed (*secY129*, *secY238*, and *secY125*). They were combined with the reaction system for in vitro transcription/translation of LacY to examine its insertion and folding. Initially, we observed that several *secY* mutant IMVs were far less active (Fig. S3, lanes 2--4; available at <http://www.jcb.org/cgi/content/full/jcb.200611121/DC1>) than wild-type IMVs (Fig. S3, lane 1). These IMVs were prepared without a urea wash. We then washed the IMVs with 4 M urea (see Materials and methods) before the assay. Remarkably, the urea wash activated the mutant IMVs, all of which exhibited LacY insertion activities that were comparable with wild-type IMVs treated in the same manner (Fig. S3, lanes 5--8). LacY synthesized in vitro remained associated with mutant IMVs even after a 5-M urea wash (Fig. S3) or alkali extraction (not depicted). It is likely that the urea wash cleared the mutated translocons by removing abnormal polypeptides so that the translocons were then capable of accepting LacY, making it possible to observe the initial integration of LacY into the mutant IMVs.

To characterize LacY inserted in vitro, immunoprecipitation was performed with mAb 4B1, which binds specifically to a conformational epitope in periplasmic loop VII/VIII of LacY ([@bib59]). LacY synthesized in vitro was inserted into urea-washed IMVs, as judged by the lack of extraction by further treatment with urea ([Fig. 5, A](#fig5){ref-type="fig"} \[lanes 1--4, 9, 10, and 13--15\] and B \[lanes 1, 2, 5, and 6\]). As shown in [Fig. 5 A](#fig5){ref-type="fig"}, mAb 4B1 binds to LacY inserted into the *secY39* ([Fig. 5 A](#fig5){ref-type="fig"}, lane 6), *secY205* ([Fig. 5 A](#fig5){ref-type="fig"}, lane 12), and *secY40* ([Fig. 5 A](#fig5){ref-type="fig"}, lane 17) IMVs as well as LacY inserted into wild-type IMVs ([Fig. 5 A](#fig5){ref-type="fig"}, lanes 5, 11, and 16). In contrast, the mAb binds much less effectively to LacY inserted into *secY129*, *secY125*, or *secY238* IMVs ([Fig. 5 A](#fig5){ref-type="fig"}, lanes 7, 8, and 18). These results strongly indicate that LacY inserted into the membrane of the *secY129*, *secY238*, or *secY125* mutant does not efficiently fold into a normal conformation.

![**Misfolding of LacY in membranes of *secY129*, *secY238*, and *secY125*.** In vitro transcription, translation, and insertion reactions were performed with 4 M urea-washed IMVs prepared from the indicated strains in the presence of ^35^S-labeled Met and Cys. After the reaction, membranes were collected carefully, subjected to a 4-M urea wash, and solubilized with a detergent. (A) Immunoprecipitation assay with a mAb 4B1. LacY inserted in vitro into IMVs was visualized by SDS-PAGE and autoradiography either directly (lanes 1--4, 9, 10, and 13--15; 5% of the total sample was used) or after immunoprecipitation using mAb 4B1 (lanes 5--8, 11, 12, and 16--18; the rest of the sample was used). It should be noted that the smearing bands at the top regions of the gels also represent the LacY protein, which is known to be prone to aggregation in the presence of SDS. The graph indicates the LacY recovery in the immunoprecipitates as expressed relative to that achieved using wild-type IMV. Data from several independent experiments are averaged, with error bars indicating the SD. IMVs were prepared from TY0 (*secY* ^+^), AD208 (*secY39*), TY24 (*secY129*), and TY8 (*secY125*) for lanes 1--8 and SH463 (*secY* ^+^), SH464 (*secY205*), SH467 (*secY40*), and SH469 (*secY238*) for lanes 9--18. (B) Immunoprecipitation assay with mAb 4B11. The experiment was performed as in A using mAb 4B11 for immunoprecipitation as indicated. IMVs were prepared from TY0 (*secY* ^+^), TY24 (*secY129*), TY8 (*secY125*), and AD2397 (*secY238*).](jcb1760307f05){#fig5}

Another mAb, 4B11, recognizes a discontinuous epitope that contains determinants from both loops VIII/IX and X/XI on the cytoplasmic surface of LacY ([@bib60]; [@bib45]). As shown in [Fig. 5 B](#fig5){ref-type="fig"} (lanes 4 and 8), mAb 4B11 binds very weakly to LacY synthesized in vitro with *secY129* and *secY125* IMVs as compared with the mAb binding to LacY inserted into wild-type vesicles ([Fig. 5 B](#fig5){ref-type="fig"}, lanes 3 and 7). The *secY238* IMVs also exhibited a lower than normal ability to support the LacY folding ([Fig. 5 B](#fig5){ref-type="fig"}, lane 12). Thus, LacY is misfolded in *secY129*, *secY125*, and *secY238* membranes. There is an excellent correlation between the LacY folding defect and the stress response induction ([Table I](#tbl1){ref-type="table"}).

To address the in vivo significance of the aforementioned findings, we examined the stability of newly synthesized and membrane-integrated LacY-His~10~ by pulse-chase experiments in which membranes were isolated, washed with urea, and subjected to affinity isolation. Thus, LacY-His~10~ was expressed in *secY* ^+^, *secY39*, *secY205*, *secY40*, *secY129*, *secY238*, and *secY125* cells, which were labeled briefly with \[^35^S\]methionine and chased with unlabeled methionine for 1, 2, and 4 min. As reported previously ([@bib45]), LacY was stably maintained in membranes of wild-type cells ([Fig. 6](#fig6){ref-type="fig"}, top). Its stability was not affected adversely in the *secY39*, *secY205*, or *secY40* mutant ([Fig. 6](#fig6){ref-type="fig"}). In contrast, LacY was markedly destabilized in the *secY125* mutant such that the radioactive band decreased to an almost undetectable level after a 4-min chase ([Fig. 6](#fig6){ref-type="fig"}). LacY synthesized in the *secY129* and *secY238* mutants was also unstable, although less so than in the *secY125* mutant. These results are consistent with the notion that LacY molecules that were membrane integrated in the *secY125*, *secY129*, and *secY238* mutants are degraded by a proteolytic mechanism of the cell, presumably as a result of a failure in folding. They agree well with the results obtained in the in vitro experiments. Collectively, we conclude that LacY, a paradigm for polytopic membrane proteins, is misfolded when membrane insertion is mediated by a translocon with the SecY129, SecY238, or SecY125 alteration.

![**LacY is destabilized in membrane protein folding--defective *secY* mutants.** LacY-His~10~ was expressed in isogenic strains TY0 (*secY* ^+^), AD208 (*secY39*), TY24 (*secY129*), and TY8 (*secY125*) in the left panels and SH463 (*secY* ^+^), SH464 (*secY205*), SH467 (*secY40*), and SH469 (*secY238*) in the right panels as described in Materials and methods. Cells were pulse labeled for 1 min with radioactive \[^35^S\]methionine and cysteine and were chased with excess amounts of nonradioactive methionine and cysteine for the indicated time periods. Membranes were isolated from the labeled cells and washed with urea. LacY was isolated from the urea-washed membranes by means of metal affinity chromatography, subjected to SDS-PAGE, and autoradiographed.](jcb1760307f06){#fig6}

Discussion
==========

The results presented in this paper extend our previous conclusion that abnormal plasma membrane proteins can generate a stress that is sensed by the Cpx signal transduction mechanism ([@bib56]). Failure in membrane protein biogenesis can generate a stress that is sensed by the Cpx and the σ^E^ regulatory mechanisms that have generally been believed to sense protein abnormalities at the outer membrane--periplasmic regions of the cell. The Cpx pathway induction in *E. coli* mutants lacking phosphatidylethanolamine ([@bib35]) may also be ascribed to the generation of some malfolded membrane proteins. The Cpx and σ^E^ regulatory systems contain both plasma membrane--integrated and periplasmic components ([@bib15]; [@bib20]), and some of them could participate in this sensing. Molecular mechanisms of membrane stress recognition are emerging new subjects.

In contrast to the YidC and SecDF defects, the *ffh* SRP defects that occur at the targeting step do not elicit the envelope stress responses; instead, the σ^32^-mediated cytosolic stress response is up-regulated under Ffh-compromised conditions ([@bib9]; [@bib48]). It is noteworthy that the *secY40*, *secY299*, and *secY403* mutants are defective in membrane protein insertion but are only weak or insignificant inducers of envelope stress responses. It is possible that some of these mutations primarily affect the targeting step of membrane protein assembly. Indeed, synthetic phenotypes with SRP alterations have been described previously for the *secY40* mutation ([@bib46]; [@bib7]) affecting a cytosolically exposed part of SecY ([@bib64]).

Importantly, we have identified several amino acid substitutions in SecY that not only impair membrane protein biogenesis but also induce the extracytoplasmic stress responses. A formal possibility that the altered SecY protein itself is sensed as malfolded by the stress response mechanisms is unlikely for the following reasons. First, stress response induction is abolished by the introduction of wild-type *secY* in trans (unpublished data), indicating that a loss of function is responsible. Second, the *secY238*, *secY299*, *secY351*, and *secY129* mutants are nearly normal in the protein export ability, making it unlikely that the mutated SecY proteins have been considerably denatured. We propose that the *secY* mutations lead to membrane protein biogenesis failures, generating abnormally folded proteins within the plasma membrane. This stress response seems to be mechanistically distinct from the phage shock protein induction associated with some *yidC* and *sec* defects ([@bib26]), as we confirmed the lack of PspA induction in some of the SecY alterations (unpublished data).

Conclusive evidence that a class of *secY* alterations lead to inserted but abnormally folded membrane proteins came from our analyses of in vitro translation and integration of LacY. In vitro--synthesized LacY inserted competently into urea-washed membrane vesicles from the *secY* mutants in manners that were resistant to further treatment with urea, which removes LacY molecules only peripherally attached to the membrane ([@bib51]; [@bib44]). Strikingly, however, there is a clear distinction between LacY molecules synthesized in the presence of the wild type, SecY39, SecY40, or SecY205 IMVs and those synthesized in the presence of the SecY125, SecY129, or SecY238 IMVs. Whereas the products of the former reactions react with the conformation-specific mAbs against LacY, the products of the latter reaction do so only weakly. These antibodies have been used to probe folding states of this integral membrane protein under a variety of conditions, including the presence or absence of YidC ([@bib10]; [@bib45]).

Thus, we conclude that a class of *secY* mutations alters the translocon in such a way that its function to effectively support the folding of membrane proteins, at least that of LacY, is compromised. Consistent with this notion, LacY is destabilized in these mutant cells. Unstable LacY is also produced in YidC-depleted cells ([@bib45]). Our results showing that such SecY defects are accompanied by the induction of membrane stresses suggest that the folding-assisting role of SecY is not limited toward LacY but is exerted toward several membrane proteins. Previously, [@bib49] showed that the *prlA* class of *secY* mutations affects localization of the PhoA domain attached to a membrane protein. However, the significance of this observation with respect to the normal function of SecY in membrane protein assembly is obscure; for instance, this mode of PhoA translocation depends on SecB, which is considered to be unrelated to membrane protein integration. [@bib19] described that in yeast, some *Sec61* mutations affect the topological preference of a mutated transmembrane (TM) segment that naturally assumes dual orientations. Our present observations with SecY are distinct from the aforementioned precedents in that the mutations impair folding of a native, unaltered membrane protein, LacY.

Different amino acid substitutions of SecY affected OmpA export and MalF-PSBT/SecY-PhoA insertion differentially ([Table I](#tbl1){ref-type="table"}). Because the *secY39* and *secY205* alterations, which impair export but not integration, are suggested to affect aspects of SecY--SecA interactions ([@bib32]; [@bib39], [@bib41]), it is conceivable that the aforementioned differentiation comes from the differential utilization of SecA by exported versus membrane proteins ([@bib28]). However, it should be noted that insertion of both MalF-PSBT ([@bib25]) and SecY-PhoA (unpublished data) depends on SecA. Intriguingly, we showed that export of a periplasmic protein, DsbA, exhibits a similar spectrum of dependence on different *secY* mutations as the membrane protein integration studied here ([@bib57]). As [@bib55] argue, higher hydrophobicity of the signal sequence of DsbA might direct it to the SRP-dependent pathway of translocation. Thus, membrane proteins and DsbA may use a targeting route different from that used by OmpA and maltose-binding protein, and the mode of targeting may determine the mode of translocon utilization. Recently, [@bib38] speculated on the basis of their electron microscopic data of *E. coli* SecYEG, which is in complex with the ribosome bearing a nascent membrane protein, that a working form of SecYEG is its front-to-front dimer. Furthermore, they proposed that the two SecYEG units are nonidentical such that one of them has a more hydrophobic channel than the other. Although this model should be examined critically by higher resolution structural studies, it offers a nice explanation for our finding of differential translocon utilization by different classes of exported or membrane proteins.

We mapped positions affected by the five membrane protein folding--defective SecY alterations on the 3D structure of *E. coli* SecY ([@bib42]) modeled on the basis of the published coordinates for the *Methanococcus jannaschii* SecYEβ complex ([@bib64]). Although the mutations are located in diverse positions of SecY (Fig. S4, available at <http://www.jcb.org/cgi/content/full/jcb.200611121/DC1>), some comments are possible. First, Ala351 (the site of *secY351* mutation) is located within the cytosolic loop 5 (C5), which is of implicated importance in the interaction with SecA or the ribosome. Second, Glu238 (*secY238*) and Cys385 (*secY129*) are located near the cytosolic end of TM6 (before C4) and TM9 (after C5), respectively, which face each other. Finally, *secY125* and *secY124*, impairing both export and integration, are mapped within regions of implicated importance in vertical and/or lateral gating of the translocon ([@bib64]). Ser76 (the site of the *secY125* alteration) is located near the C-terminal end of the short plug helix called TM2a by [@bib64]. The bulky Phe residue here may compromise the proposed movement of this plug toward the periplasm to open the gate, which is in agreement with the late step translocation defect by *secY125* ([@bib33]). Our results seem to suggest that this plug movement is also important for the effective clearance of the pore by the lateral release of a membrane protein. Pro84 (*secY124*) is located in the middle of TM2. The importance of Pro84 in membrane protein integration has been suggested from our reisolation of the same Pro84-Leu substitution by the new mutant screening designed for membrane stress induction ([Table I](#tbl1){ref-type="table"}). The TM2, TM7, and TM3 regions of SecY were proposed to comprise the lateral gate, through which substrate signal peptide or a region destined to a TM configuration moves in or out ([@bib64]). Pro84 in TM2 could contribute to the gate-opening function possibly by perturbing the helix structure of this TM segment.

How does SecY contribute to the correct folding of membrane proteins? One obvious function is to recognize a TM sequence and assist its movement out of the translocon. Additionally, it may have a role of reorienting a hydrophobic segment to generate its correct TM topology ([@bib18]; [@bib19]). Finally, SecY may interact with SecDF and/or YidC to create a productive assembly line for a membrane protein to follow. Each of the membrane protein folding--defective mutations identified in this study may affect one of the aforementioned functions or still other functions of the SecY translocon, and their further analysis will be useful for our full understanding of the mechanisms of membrane protein integration and folding that occur in living cells.

Materials and methods
=====================

Media
-----

Minimal medium M9 ([@bib36]) and complete nutrient medium L (containing 10 g bacto-tryptone, 5 g of yeast extract, and 5 g NaCl per liter; pH was adjusted to 7.2 by NaOH) were used. For growing plasmid-carrying strains, 50 μg/ml ampicillin, 20 μg/ml chloramphenicol, and/or 25 μg/ml tetracycline were added to the medium.

Bacterial strains and plasmids
------------------------------

The following *E. coli* K-12 strains were used in this study. MC4100 (*araD139* Δ\[*argF-lac*\]*U169 rpsL150 relA1 flbB5301 deoC1 ptsF25 rbsR*; [@bib11]) was used as a wild-type strain. KI200 (MC4100, *rplO*am215 Tn*10* \[φ80*sus2*p*supF* ^ts6^\]), SP556 (MC4100, λRS88\[*degP*′*-lacZ* ^+^\]), and NH192 (MC4100, *secE501*\[Cs\]) were previously described by [@bib24], [@bib56], and [@bib34]; note that NH192 was erroneously named as NH195 in this reference), respectively. AD202, an *ompT*∷*kan* derivative of MC4100 ([@bib3]), was the parental strain for the following strains: TY0 (*rpsE secY* ^+^ *zhd33*∷Tn*10*), TY8 (*rpsE secY125 zhd33*∷Tn*10*), TY24 (*rpsE secY129 zhd33*∷Tn*10*), and AD208 (*secY39 zhd33*∷Tn*10*; [@bib8]; [@bib62]; for TY strains). SKP1101 (MC4100, *ara* ^+^ *ffh1*∷*kan*/pSKPP10) and SKP1102 (MC4100, *ara* ^+^ *ffh1*∷*kan*/pSKPP11) carried *ffh10*(Ts) and the wild-type allele of *ffh* on the plasmids, respectively (obtained from G. Phillips, Iowa State University, Ames, IA; [@bib48]). The YidC conditional expression strain JS7131 (MC1060, Δ*yidC attB*∷*R6Kori* P~*araBAD*~-*yidC* ^+^ \[Spec^r^\]), having the chromosomal *yidC* disruption and arabinose promoter-controlled copy of *yidC*, and its isogenic *yidC* ^+^ strain JS71 were described previously ([@bib53]).

MC4100 mutants having *secY* alleles, SH470 (*secY39*), SH464 (*secY205*), SH465 (*secY125*), SH466 (*secY124*), SH467 (*secY40*), and SH468 (*secY129*), were constructed by cotransduction of the respective *secY* mutations in the original mutants ([@bib23]; [@bib62]) with *zhd33*∷Tn*10*. Note that the *secY115* mutation ([@bib62]) is identical to *secY40* ([@bib8]). SH625 (*secD1*) was a *secD1 zaj*∷Tn*10* transductant of MC4100 using THE521 ([@bib27]) as a donor. SH463 (MC4100, *rpsE secY* ^+^ *zhd33*∷Tn*10*) and SH117 (SP556, *secY* ^+^ *zhd33*∷Tn*10*) were used for *secY* ^+^ control experiments.

Plasmid pSTD343 ([@bib52]) was a derivative of pSTV29 (Takara Shuzo) that carried *lacI* ^q^ derived from pREP4 (QIAGEN). Plasmid pSTD643 carrying a *rpoHP3-lacZ* transcriptional fusion was constructed by cloning the P3 promoter region of *rpoH*, which was amplified from the MC4100 chromosome using primers 5′-CCG[GAATTC]{.ul}ATACTCTTTCCC TGCAATGGG-3′ and 5′-CGC[GGATCC]{.ul}CAACGAGGTTATCATTCACTG-3′ (EcoRI and BamHI recognition sequences are underlined), into pFZY1 ([@bib29]) after digestion with these enzymes. Plasmid pKY4-3-3 carried the *secY-phoA(3-3)* gene fusion under the *lac* promoter ([@bib2]). Plasmid pSH10 carried the *cpxP*′-*lacZ* ^+^ transcriptional fusion controlled by the Cpx regulatory pathway ([@bib56]). Plasmid pGJ78-J carried a PSBT domain fused to the second periplasmic domain of MalF under the *lac* promoter ([@bib25]).

Identification of new *secY* alleles by screening of localized chromosomal mutations for those up-regulating the extracytoplasmic stress responses
--------------------------------------------------------------------------------------------------------------------------------------------------

Localized mutagenesis of the chromosomal region around *zhd33*∷Tn*10* and screening for SecY-affected mutants were performed as described previously ([@bib62]) except that SP556 (*degP*′-*lacZ* ^+^) was used as a recipient in P1 transduction ([@bib36]). Blue-colored transductants were looked for on [l]{.smallcaps}-agar palates containing 25 μg/ml tetracycline, 40 μg/ml X-gal (5-bromo-4-chloro-3-indolyl-β-[d]{.smallcaps}-galactopyranoside), and 0.5 mM phenylethyl-thiogalactoside at 30 or 37°C. They were purified and checked for growth phenotypes at 20, 30, 37, and 42°C. Plasmid pHMC5A (*secY* ^+^; [@bib39]) was then introduced to examine whether the growth defect (if any) and color development on the X-gal plates were corrected. Those complemented were further tested for cotransduction of the phenotypes with *zhd33*∷Tn*10* when they were used as a donor in backcross P1 transduction into the original recipient. We established each mutant by saving a transductant with the mutant phenotypes at this stage, which was further subjected to sequence determination for the *secY* ORF. Mutants thus established are summarized below in a format of allele name given, nucleotide changes with a deduced amino acid change in parentheses, and growth phenotypes (Ts, Cs, and Ts/Cs indicate poor growth at 42°C, 20°C, and at both of these temperatures, respectively): *secY84*, C251T (Pro84-Leu) and C3901T (silent), Cs; *secY238*, G712A (Glu238-Lys), Cs; *secY299*, G896 (Gly299-Glu), Ts; *secY351*, G1051A (Ala351-Thr), Ts/Cs; and *secY403*, G1207A (Gly403-Arg). The amino acid substitution by *secY84* is identical to that by *secY124*; thus, data for *secY84* were omitted. Established strains of the SP556 (*degP*′-*lacZ* ^+^) background were named SH237 (*secY238*), SH245 (*secY299*), SH247 (*secY351*), and SH253 (*secY403*). We also used these mutants of the MC4100 background named SH469 (*secY238*), SH472 (*secY299*), and SH471 (*secY351*) as well as AD2397 (AD202; *secY238*).

An insertion reporter, MalF-PSBT(J)
-----------------------------------

The MalF-PSBT(J) fusion protein contains a biotinylatable domain (PSBT) fused to the second periplasmic domain of MalF, which is biotinylated in vivo only when it resides in the cytosol for an extended period ([@bib25]). Thus, it reports an insertion defect by increased biotinylation. The control fusion protein MalF-PSBT(K) contains PSBT fused to a cytosolic domain of MalF and is readily biotinylated in any strain of *E. coli* having the normal biotinylating enzyme.

Protein analyses
----------------

Protein pulse labeling with \[^35^S\]methionine, chase with unlabeled methionine, and immunoprecipitation were performed essentially as described previously ([@bib8]). Antisera against maltose-binding protein, OmpA, and the N-terminal region of SecY were described previously ([@bib58]). Anti-MalF and anti-YidC sera were provided by J. Beckwith (Harvard Medical School, Boston, MA) and R.E. Dalbey (Ohio State University, Columbus, OH), respectively. Radioactive proteins after SDS-PAGE were visualized and quantified by a phosphorimager (BAS1800; Fuji). Immunoblotting was performed as described previously ([@bib58]) using SDS-solubilized cellular proteins equivalent to those of ∼10^7^ cells. Biotinylated proteins were detected with streptavidin-conjugated HRP (GE Healthcare). Protein images were visualized and quantified by a lumino-imager (LAS1000; Fuji). β-galactosidase activity was assayed as described previously ([@bib36]); averaged values of at least three independent determinations were reported with error bars.

In vitro transcription, translation, insertion, and immunoprecipitation of LacY
-------------------------------------------------------------------------------

IMVs for this assay were prepared as described previously ([@bib44]) from cells cultured at 37°C. Where specified, they were washed with 4 M urea ([@bib43]) before in vitro LacY insertion reactions. In vitro LacY transcription, translation, and insertion were performed at 30°C for 30 min in the presence of IMVs as described previously ([@bib45]). Subsequently, membranes were collected by centrifugation through a 50% sucrose cushion and washed with 4 M urea to obtain membrane-inserted LacY. The reactivity of LacY with conformation-specific mAb 4B1 or 4B11 was assessed by a previously described immunoprecipitation assay ([@bib45]) with minor modifications: reaction mixtures were incubated at 4°C for 3 h with protein A beads, which were recovered after dilution with wash buffer and an additional incubation for 15 min, and washings were repeated five times.

Pulse-chase assay of LacY stability
-----------------------------------

Cells transformed with both a LacY-His~10~ expression plasmid ([@bib21]) and a *lacI^q^* plasmid (pSTD343) were precultured in LB-ampicillin--chloramphenicol (100 μg/ml and 34 μg/ml, respectively) medium at 37°C overnight, centrifuged down, washed with M9 minimal medium, and inoculated into 50 vol M9 medium supplemented with amino acids (except Met and Cys) and thiamine for further growth at 37°C. Cells were then induced for the *lac* transcription with 1 mM IPTG for 5 min at OD~600~ = 0.6--0.8 and were pulse labeled with \[^35^S\]Tran (MP Biomedicals) for 1 min followed by chase with excess concentrations of unlabeled Met and Cys for indicated times. Samples were placed on ice, and cells were harvested by centrifugation. Membranes were prepared by sonification and subjected to a 5-M urea wash as described previously ([@bib65]; [@bib45]). Radioactive LacY-His~10~ was isolated by metal affinity chromatography and visualized as described previously ([@bib45]).

Online supplemental material
----------------------------

Fig. S1 provides graphical explanations of different types of membrane protein biogenesis defects. Fig. S2 shows the results of integration assays using the SecY-PhoA(3-3) fusion protein. Fig. S3 shows LacY integration activities of IMVs prepared from *secY* mutants as well as their activation by urea washings. Fig. S4 shows locations of the membrane protein folding--impairing amino acid substitutions on the 3D structure of SecY. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.200611121/DC1>.
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